Literature DB >> 8640376

A direct binding assay for the vascular cell adhesion molecule-1 (VCAM1) interaction with alpha 4 integrins.

R R Lobb1, G Antognetti, R B Pepinsky, L C Burkly, D R Leone, A Whitty.   

Abstract

Vascular cell adhesion molecule-1 (VCAM1) is a member of the immunoglobulin (Ig) superfamily which interacts with the alpha 4 integrins alpha 4 beta 1 (very late antigen 4: VLA4) and alpha 4 beta 7, which are constitutively expressed on many leukocyte subsets and play a key role in cell trafficking and activation. Using a recombinant VCAM-IgG fusion protein (VCAM-Ig) as a soluble ligand for alpha 4 beta 1 we directly demonstrated by fluorescence analysis that the alpha 4 beta 1 receptor can exist in different affinity states on the cell surface, and that a high affinity state is induced by manganese ions or certain activating anti-beta 1 monoclonal antibodies (Jakubowski et al., 1995b). Here we have extended these observations by developing a rapid and reproducible assay using alkaline phosphatase (AP)-coupled VCAM-Ig (VCAM-Ig-AP) which measures the interaction between VCAM1 and alpha 4 integrins in a microtiter plate format. This assay has allowed us to evaluate directly the effects of metal ions, anti-beta 1 mAbs, and different cell types and species on the VCAM1/alpha 4 integrin interaction. Most importantly, the assay system provides a means to rapidly evaluate alpha 4 integrin-directed inhibitors without the complication of post-ligand binding events inherent in adhesion assays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8640376     DOI: 10.3109/15419069509081293

Source DB:  PubMed          Journal:  Cell Adhes Commun        ISSN: 1023-7046


  8 in total

1.  Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1.

Authors:  B Leitinger; N Hogg
Journal:  Mol Biol Cell       Date:  2000-02       Impact factor: 4.138

2.  3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists.

Authors:  Juswinder Singh; Herman van Vlijmen; Wen-Chemg Lee; Yusheng Liao; Ko-Chung Lin; Humayun Ateeq; Julio Cuervo; Craig Zimmerman; Charles Hammond; Michael Karpusas; Rex Palmer; Tapan Chattopadhyay; Steven P Adams
Journal:  J Comput Aided Mol Des       Date:  2002-03       Impact factor: 3.686

Review 3.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

4.  Defining extracellular integrin alpha-chain sites that affect cell adhesion and adhesion strengthening without altering soluble ligand binding.

Authors:  C Pujades; R Alon; R L Yauch; A Masumoto; L C Burkly; C Chen; T A Springer; R R Lobb; M E Hemler
Journal:  Mol Biol Cell       Date:  1997-12       Impact factor: 4.138

5.  Active site formation, not bond kinetics, limits adhesion rate between human neutrophils and immobilized vascular cell adhesion molecule 1.

Authors:  Richard E Waugh; Elena B Lomakina
Journal:  Biophys J       Date:  2009-01       Impact factor: 4.033

6.  Chemoattractants induce a rapid and transient upregulation of monocyte alpha4 integrin affinity for vascular cell adhesion molecule 1 which mediates arrest: an early step in the process of emigration.

Authors:  J R Chan; S J Hyduk; M I Cybulsky
Journal:  J Exp Med       Date:  2001-05-21       Impact factor: 14.307

7.  Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions.

Authors:  V Grabovsky; S Feigelson; C Chen; D A Bleijs; A Peled; G Cinamon; F Baleux; F Arenzana-Seisdedos; T Lapidot; R R Lobb; R Alon
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

8.  Mutational evidence for control of cell adhesion through integrin diffusion/clustering, independent of ligand binding.

Authors:  R L Yauch; D P Felsenfeld; S K Kraeft; L B Chen; M P Sheetz; M E Hemler
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.